GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » Cyclically Adjusted PB Ratio

InMed Pharmaceuticals (InMed Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.01 (As of Jun. 09, 2024)


View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-09), InMed Pharmaceuticals's current share price is $0.2354. InMed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $36.34. InMed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.01.

The historical rank and industry rank for InMed Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

INM' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.04   Max: 1.06
Current: 0.01

During the past years, InMed Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 1.06. The lowest was 0.01. And the median was 0.04.

INM's Cyclically Adjusted PB Ratio is ranked better than
99.85% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs INM: 0.01

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

InMed Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was $1.750. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $36.34 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


InMed Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for InMed Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Cyclically Adjusted PB Ratio Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 8.95 2.74 0.35 0.03

InMed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.02 0.01 0.01

Competitive Comparison of InMed Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, InMed Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



InMed Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

InMed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.2354/36.34
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, InMed Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.75/126.2576*126.2576
=1.750

Current CPI (Mar. 2024) = 126.2576.

InMed Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 30.701 99.473 38.968
201409 25.469 99.394 32.353
201412 18.123 98.367 23.262
201503 18.123 99.789 22.930
201506 18.210 100.500 22.877
201509 12.915 100.421 16.238
201512 9.835 99.947 12.424
201603 6.790 101.054 8.484
201606 9.914 102.002 12.272
201609 10.654 101.765 13.218
201612 13.352 101.449 16.617
201703 22.380 102.634 27.531
201706 39.585 103.029 48.510
201709 37.295 103.345 45.564
201712 70.271 103.345 85.851
201803 61.452 105.004 73.890
201806 99.594 105.557 119.125
201809 96.104 105.636 114.865
201812 85.386 105.399 102.284
201903 77.829 106.979 91.854
201906 66.480 107.690 77.942
201909 54.226 107.611 63.622
201912 44.285 107.769 51.882
202003 32.543 107.927 38.070
202006 28.147 108.401 32.783
202009 21.520 108.164 25.120
202012 27.108 108.559 31.527
202103 32.339 110.298 37.018
202106 22.908 111.720 25.889
202109 36.850 112.905 41.208
202112 25.053 113.774 27.802
202203 19.055 117.646 20.450
202206 13.953 120.806 14.583
202209 12.113 120.648 12.676
202212 9.016 120.964 9.411
202303 3.722 122.702 3.830
202306 3.633 124.203 3.693
202309 2.878 125.230 2.902
202312 2.253 125.072 2.274
202403 1.750 126.258 1.750

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


InMed Pharmaceuticals  (NAS:INM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


InMed Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (InMed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Executives
Jonathan Tegge officer: Interim CFO 217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li officer: VP, Accounting and Controller 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric A Adams director, officer: President & CEO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Brenda Edwards officer: Interim CFO 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove director 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill officer: CFO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson officer: SVP & GM of BayMedica LLC 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler director 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu officer: Sr. VP, Pre-Clinical Res/Dev C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Michael Woudenberg officer: VP, Chem/Manufacturing/Control C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Mancini Alexandra Diane Janet officer: Sr VP, Clinical Reg Affairs C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4

InMed Pharmaceuticals (InMed Pharmaceuticals) Headlines